🟢 ROIV is trading 11.2% up today on Q4 results and $2.25B Moderna settlement

ROIV is trading at $31.36 (+11.2%) following Q4 FY2026 results highlighted by a $2.25 billion global patent litigation settlement with Moderna.

• The settlement contributed a $770.2 million pre-tax gain, driving GAAP EPS to $0.43 and boosting the company's cash position to $4.3 billion.
• Management highlighted a cash runway into profitability and a potential September launch for brepocitinib, improving pipeline sentiment despite the discontinuation of batoclimab.